Kintsugi Voice is an API-first platform, we are developing novel voice biomarker infrastructure to detect signs of clinical depression and anxiety from short clips of free form speech. We help healthcare organizations scale access to mental healthcare with smarter, more accurate triage. Our technology supports multiple use-cases to help more people get the right care at the right time.  We focus on early detection that allows you to lower cost and improve patient outcomes. We have created the first clinical-grade voice biomarker diagnostic (U.S. Patent-Pending and FDA De Novo pending) to measure the severity of depression and anxiety in real-time.

ActX helps physicians make better decisions about medical treatment, using patients’ genetic information. ActX uses its GenoACT℠ clinical decision support program to analyze a patient’s genetic information and alert physicians in real time through their existing workflow tool, the electronic health record, about drug-genome interactions, actionable hereditary risks and carrier status

1. Kintsugi Voice only needs 20 seconds of free from speech vs. a manual screen that takes roughly 10 minutes.
2. Kintsugi Voice is language agnostic and does not listen to what a patient is saying, but how they are saying it.
3. Kintsugi has the largest annotated patient data model, validated by a psychiatrist team with more than 7 years experience. This allows us to predict depression and anxiety with high specificity and severity, based off of PHQ-9 standards.
4. Kintsugi Voice’s flexible API enables hundreds of workflows from retrospective to live in-call scoring. Typical depression screenings are typically delivered 1 time and not longitudinal. We provide the ability to longitudinally track patients across a period of time.

1. We are not a NLP tool, we do not need any canned speech and or paragraph read to detect depression and or anxiety.
2. We have the largest annotated data model in the world with over 35k patients.
3. We are supporting over 1M at risk lives.
4. 2X accuracy rating compared to the standard of care.

Please reach out to ActX for more information.

Please reach out to ActX for more information.